Keyphrases
Multiple Sclerosis
100%
Recombinant Interferon
100%
First Demyelinating Event
100%
Glatiramer Acetate
100%
Interferon-β (IFN-β)
100%
Placebo
80%
Clinically Isolated Syndrome
80%
Immunomodulatory Drugs (IMiDs)
60%
Interferon-β Treatment
40%
Metanalysis
40%
Clinical Practice
20%
High Risk
20%
Adverse Effects
20%
Randomized Controlled Trial
20%
Cochrane
20%
Embase
20%
MEDLINE
20%
Serious Adverse Events
20%
Search Strategy
20%
Cochrane Library
20%
Placebo-controlled Randomized Trial
20%
Early Treatment
20%
Selection Criteria
20%
Clinical Heterogeneity
20%
Cochrane Central Register of Controlled Trials
20%
Relapsing-remitting multiple Sclerosis
20%
Side Effect Profile
20%
Patient Subgroups
20%
Further Analysis
20%
Initial Attack
20%
Length of Follow-up
20%
Issue 3
20%
MS-group
20%
Second Attack
20%
Demyelinating
20%
First Occurrence
20%
Trial Quality
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Beta Interferon
100%
Glatiramer
100%
Recombinant Beta Interferon
100%
Placebo
83%
Demyelinating Disease
66%
Side Effect
33%
Randomized Controlled Trial
33%
Adverse Event
33%
Symptom
16%
Group Trial
16%
Nursing and Health Professions
Multiple Sclerosis
100%
Beta Interferon
100%
Recombinant Beta Interferon
100%
Glatiramer
100%
Placebo
83%
Demyelinating Disease
66%
Cochrane Library
33%
Adverse Event
33%
Side Effect
33%
Clinical Practice
16%
Symptom
16%
Neuroscience
Multiple Sclerosis
100%
Beta Interferon
100%
Glatiramer Acetate
100%
Recombinant Beta Interferon
100%
Placebo
83%
Demyelinating Disease
66%
Randomized Controlled Trial
33%
Adverse Effect
16%
Relapsing Remitting Multiple Sclerosis
16%
Immunology and Microbiology
Multiple Sclerosis
100%
Beta Interferon
100%
Glatiramer Acetate
100%
Recombinant Beta Interferon
100%
Clinically Isolated Syndrome
66%
Immunomodulatory Drug
50%
Cochrane Library
33%
Relapsing Remitting Multiple Sclerosis
16%
Biochemistry, Genetics and Molecular Biology
interferon
100%
Interferon
100%
Cochrane Library
28%
Randomized Controlled Trial
28%
Group Trial
14%